Literature DB >> 25714683

gDNA Q-PCR for clinical monitoring of CML.

Giovanni Porta1, Ilaria Stefania Pagani1,2, Cristina Pirrone1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25714683      PMCID： PMC4825716          DOI： 10.1080/15384101.2015.1006053

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

Review 1.  Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

Authors:  John Goldman; Myrtle Gordon
Journal:  Leuk Lymphoma       Date:  2006-01

2.  Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

Authors:  Elia Mattarucchi; Orietta Spinelli; Alessandro Rambaldi; Francesco Pasquali; Francesco Lo Curto; Leonardo Campiotti; Giovanni Porta
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

Review 3.  How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Br J Haematol       Date:  2014-04-23       Impact factor: 6.998

4.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

5.  Dynamics of chronic myeloid leukaemia.

Authors:  Franziska Michor; Timothy P Hughes; Yoh Iwasa; Susan Branford; Neil P Shah; Charles L Sawyers; Martin A Nowak
Journal:  Nature       Date:  2005-06-30       Impact factor: 49.962

6.  Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia.

Authors:  Elia Mattarucchi; Vittoria Guerini; Alessandro Rambaldi; Leonardo Campiotti; Achille Venco; Francesco Pasquali; Francesco Lo Curto; Giovanni Porta
Journal:  Genes Chromosomes Cancer       Date:  2008-07       Impact factor: 5.006

7.  Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia.

Authors:  Ilaria S Pagani; Orietta Spinelli; Elia Mattarucchi; Cristina Pirrone; Diana Pigni; Elisabetta Amelotti; Silvia Lilliu; Chiara Boroni; Tamara Intermesoli; Ursula Giussani; Luigi Caimi; Federica Bolda; Renata Baffelli; Eleonora Candi; Francesco Pasquali; Francesco Lo Curto; Arnalda Lanfranchi; Fulvio Porta; Alessandro Rambaldi; Giovanni Porta
Journal:  Oncoscience       Date:  2014-07-23
  7 in total
  1 in total

1.  gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML.

Authors:  Alessia Rainero; Fabrizio Angaroni; Francesca D'Avila; Andrea Conti; Cristina Pirrone; Giovanni Micheloni; Lucia Tararà; Giorgia Millefanti; Emanuela Maserati; Roberto Valli; Orietta Spinelli; Ksenija Buklijas; Anna Michelato; Rosario Casalone; Cristina Barlassina; Matteo Barcella; Silvia Sirchia; Eleonora Piscitelli; Massimo Caccia; Giovanni Porta
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.